ArticleOncotarget2017

Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.

Avadhut D Joshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.